Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Short-Dated Bullish Options Flow in Regeneron (REGN) Following 3Q Earnings Beat -Susquehanna November 8, 2017 2:22 PM Regeneron (REGN) Tops Q3 EPS by 14c, Beats on RevenuesNovember 8, 2017 6:36 AM Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017November 7, 2017 8:01 AM